Scholarlink

Background <p>Treatment choices for patients with pathological muscularis mucosa/submucosal layer (pMM/SM1) esophageal squamous cell cancer (ESCC) after endoscopic resection (ER) are controversial.</p> Materials and methods <p>A single-center retrospective study at Beijing Cancer Hospital in China was conducted. Between February 2012 and November 2023, we retrospectively recruited patients with pMM/SM1 ESCC who underwent ER with or without subsequent adjuvant therapy. Survival was compared between groups.</p> Results <p>Overall, 93 patients were screened, and 73 patients were included. Kaplan‒Meier analysis revealed that a length of invasive cancer ≤ 10&#xa0;mm (OS, <i>P</i> = 0.025; DFS, <i>P</i> = 0.059) was a high-risk factor. Compared with the follow-up group, patients who underwent radical surgery (SR) immediately after ER demonstrated significantly shorter overall survival (OS) and disease-free survival (DFS) (OS, <i>P</i> &lt; 0.01; DFS, <i>P</i> &lt; 0.001). High-risk patients (pMM/SM1 patients with an invasive cancer length ≤ 10 mm) may benefit from chemoradiotherapy (CRT), but low-risk patients may not.</p> Conclusion <p>The length of invasive cancer ≤ 10&#xa0;mm may be a newly identified high-risk factor. CRT after ER is recommended for high-risk patients but not for low-risk patients. SR is not recommended for any patient.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment choices after endoscopic resection for pMM/SM1 esophageal squamous cell cancer: a retrospective study in China

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月4日

查看全文
  • Meichen Liu,
  • Jing Wang,
  • Qi Wu

摘要

Background

Treatment choices for patients with pathological muscularis mucosa/submucosal layer (pMM/SM1) esophageal squamous cell cancer (ESCC) after endoscopic resection (ER) are controversial.

Materials and methods

A single-center retrospective study at Beijing Cancer Hospital in China was conducted. Between February 2012 and November 2023, we retrospectively recruited patients with pMM/SM1 ESCC who underwent ER with or without subsequent adjuvant therapy. Survival was compared between groups.

Results

Overall, 93 patients were screened, and 73 patients were included. Kaplan‒Meier analysis revealed that a length of invasive cancer ≤ 10 mm (OS, P = 0.025; DFS, P = 0.059) was a high-risk factor. Compared with the follow-up group, patients who underwent radical surgery (SR) immediately after ER demonstrated significantly shorter overall survival (OS) and disease-free survival (DFS) (OS, P < 0.01; DFS, P < 0.001). High-risk patients (pMM/SM1 patients with an invasive cancer length ≤ 10 mm) may benefit from chemoradiotherapy (CRT), but low-risk patients may not.

Conclusion

The length of invasive cancer ≤ 10 mm may be a newly identified high-risk factor. CRT after ER is recommended for high-risk patients but not for low-risk patients. SR is not recommended for any patient.